Clinical Trial of EPI-743 in Patients with Leigh Syndrome [Extended Treatment Study]
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Vatiquinone (Primary)
- Indications Leigh disease
- Focus Therapeutic Use
- Sponsors Sumitomo Pharma
- 05 Apr 2022 Status changed from active, no longer recruiting to completed.
- 17 Mar 2017 Planned End Date changed from 1 Sep 2016 to 31 Oct 2024.
- 17 Jun 2016 New trial record